A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
- DOI
- 10.1093/rheumatology/keaa410
- Published
- 2021 Mar 2
- Container
- Rheumatology (Oxford, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/rheumatology/keaa410,
title = {A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.},
author = {Juarez M and Diaz N and Johnston GI and Nayar S and Payne A and Helmer E and Cain D and Williams P and Devauchelle-Pensec V and Fisher BA and Giacomelli R and Gottenberg JE and Guggino G and Kvarnström M and Mariette X and Ng WF and Rosas J and Sánchez Bursón J and Triolo G and Barone F and Bowman SJ},
year = {2021},
journal = {Rheumatology (Oxford, England)},
doi = {10.1093/rheumatology/keaa410},
url = {https://doi.org/10.1093/rheumatology/keaa410}
}RIS
TY - JOUR TI - A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. AU - Juarez M AU - Diaz N AU - Johnston GI AU - Nayar S AU - Payne A AU - Helmer E AU - Cain D AU - Williams P AU - Devauchelle-Pensec V AU - Fisher BA AU - Giacomelli R AU - Gottenberg JE AU - Guggino G AU - Kvarnström M AU - Mariette X AU - Ng WF AU - Rosas J AU - Sánchez Bursón J AU - Triolo G AU - Barone F AU - Bowman SJ PY - 2021 JO - Rheumatology (Oxford, England) DO - 10.1093/rheumatology/keaa410 UR - https://doi.org/10.1093/rheumatology/keaa410 ER -
APA
M, J., N, D., GI, J., S, N., A, P., E, H., D, C., P, W., V, D., BA, F., R, G., JE, G., G, G., M, K., X, M., WF, N., J, R., J, S. B., G, T., F, B., & SJ, B. (2021). A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.. Rheumatology (Oxford, England). https://doi.org/10.1093/rheumatology/keaa410
Source records
- pubmed · retrieved 2026-09-27T14:05:53.996Z